Zacks Research Has Positive Forecast for VRTX Q2 Earnings

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) – Analysts at Zacks Research increased their Q2 2025 EPS estimates for shares of Vertex Pharmaceuticals in a research report issued on Wednesday, October 23rd. Zacks Research analyst R. Department now forecasts that the pharmaceutical company will post earnings per share of $4.09 for the quarter, up from their previous forecast of $4.04. The consensus estimate for Vertex Pharmaceuticals’ current full-year earnings is ($2.11) per share. Zacks Research also issued estimates for Vertex Pharmaceuticals’ Q3 2025 earnings at $3.97 EPS, Q4 2025 earnings at $4.01 EPS, FY2025 earnings at $15.93 EPS, Q1 2026 earnings at $4.08 EPS and Q3 2026 earnings at $4.44 EPS.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings results on Thursday, August 1st. The pharmaceutical company reported ($12.83) EPS for the quarter, missing the consensus estimate of ($12.54) by ($0.29). The company had revenue of $2.65 billion during the quarter, compared to analysts’ expectations of $2.66 billion. Vertex Pharmaceuticals had a negative return on equity of 2.45% and a negative net margin of 4.74%. The company’s quarterly revenue was up 6.1% on a year-over-year basis. During the same period in the prior year, the business earned $3.53 EPS.

Several other research analysts have also recently issued reports on the stock. UBS Group increased their target price on shares of Vertex Pharmaceuticals from $477.00 to $562.00 and gave the stock a “buy” rating in a report on Thursday, October 17th. Barclays cut shares of Vertex Pharmaceuticals from an “overweight” rating to an “equal weight” rating and increased their target price for the stock from $472.00 to $509.00 in a report on Monday, August 5th. Raymond James reiterated a “market perform” rating on shares of Vertex Pharmaceuticals in a report on Thursday, October 10th. Scotiabank began coverage on shares of Vertex Pharmaceuticals in a report on Wednesday, October 16th. They set a “sector perform” rating and a $480.00 target price on the stock. Finally, TD Cowen increased their target price on shares of Vertex Pharmaceuticals from $450.00 to $500.00 and gave the stock a “buy” rating in a report on Tuesday, July 23rd. Three research analysts have rated the stock with a sell rating, ten have issued a hold rating and seventeen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Vertex Pharmaceuticals currently has an average rating of “Hold” and an average target price of $492.92.

Vertex Pharmaceuticals Trading Up 1.2 %

VRTX stock opened at $477.70 on Thursday. The company has a market capitalization of $123.27 billion, a PE ratio of 31.00 and a beta of 0.40. Vertex Pharmaceuticals has a 12 month low of $341.90 and a 12 month high of $510.64. The firm’s 50-day moving average is $475.60 and its 200 day moving average is $461.36. The company has a debt-to-equity ratio of 0.02, a current ratio of 2.52 and a quick ratio of 2.26.

Hedge Funds Weigh In On Vertex Pharmaceuticals

Institutional investors have recently made changes to their positions in the company. Northwest Investment Counselors LLC purchased a new position in shares of Vertex Pharmaceuticals during the 3rd quarter valued at approximately $25,000. Annapolis Financial Services LLC purchased a new position in shares of Vertex Pharmaceuticals during the 1st quarter valued at approximately $27,000. Highline Wealth Partners LLC purchased a new position in shares of Vertex Pharmaceuticals during the 3rd quarter valued at approximately $27,000. GHP Investment Advisors Inc. purchased a new position in shares of Vertex Pharmaceuticals during the 2nd quarter valued at approximately $29,000. Finally, Stephens Consulting LLC purchased a new position in shares of Vertex Pharmaceuticals during the 2nd quarter valued at approximately $31,000. 90.96% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Vertex Pharmaceuticals news, Chairman Jeffrey M. Leiden sold 3,784 shares of the firm’s stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $499.00, for a total transaction of $1,888,216.00. Following the completion of the transaction, the chairman now directly owns 9,994 shares of the company’s stock, valued at approximately $4,987,006. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In other Vertex Pharmaceuticals news, Chairman Jeffrey M. Leiden sold 3,784 shares of the firm’s stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $499.00, for a total transaction of $1,888,216.00. Following the completion of the transaction, the chairman now directly owns 9,994 shares of the company’s stock, valued at approximately $4,987,006. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Sangeeta N. Bhatia sold 646 shares of the firm’s stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $500.00, for a total transaction of $323,000.00. Following the transaction, the director now directly owns 4,435 shares of the company’s stock, valued at $2,217,500. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 12,005 shares of company stock valued at $5,988,066. 0.20% of the stock is owned by insiders.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.